

1. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus
2. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
3. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
4. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis
5. SGLT-2 INHIBITORS DEMONSTRATE CONSISTENT REDUCTION IN CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATIONS AN UP-TO-DATE META-ANALYSIS
6. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure
7. META-ANALYSIS EVALUATING THE EFFICACY OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS IN SUBJECTS WITH HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
8. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure
9. Meta-analysis of SGLT inhibitors on cardiovascular death or heart failure hospitalisation based on presence of type 2 diabetes, heart failure, or chronic kidney disease
10. Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia
11. Meta-Analysis Evaluating Dapagliflozin in Heart Failure Reduced Ejection Fraction: A Focus on Left Ventricular Remodeling
12. A META-ANALYSIS ASSESSING THE EFFECT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS ON SURROGATE ENDPOINTS IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
13. Kidney function after initiation and discontinuation of empagliflozin in heart failure patients with and without type 2 diabetes: insights from the empirical trials
14. Impact of Dapagliflozin on Mortality in Patients With Heart Failure and Reduced Ejection Fraction: A Meta-analysis
15. [Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review]
16. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
17. Efficacy and safety of SGLT2 inhibitors in patients with heart failure A protocol for systematic review and meta-analysis
18. Efficacy and safety of dapagliflozin in the treatment of chronic heart failure A protocol for systematic review and meta-analysis
19. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials

20. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: A systematic review and meta-analysis
21. EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES AND ALL CAUSE MORTALITY: A REVIEW AND META-ANALYSIS
22. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes -Systematic review and meta-analysis of randomized placebo-controlled trials
23. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
24. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
25. Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
26. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
27. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: a Participant-Level Pooled Analysis of DAPA-HF and DELIVER
28. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
29. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
30. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
31. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
32. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: a Secondary Analysis of EMPEROR-Pooled
33. Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation
34. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
35. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
36. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
37. Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
38. Meta-Analysis of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure

Patients Without Diabetes

39. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
40. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
41. Meta analysis of the effect of dapagliflozin on blood glucose and cardiovascular risk factors in patients with type 2 diabetes
42. Meta analysis of the effect of dapagliflozin on cardiovascular safety in patients with type 2 diabetes
43. Meta analysis and sequential trial analysis of the effect of SGLT2 inhibitor on cardiovascular adverse events in type 2 diabetes patients with cardiovascular disease
44. Treatment of patients with chronic heart failure with dapagliflozin: systematic review and meta analysis
45. Meta analysis of the efficacy and safety of dapagliflozin in the treatment of chronic heart failure
46. Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure
47. Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction
48. A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction
49. Use of SGLT2 inhibitors and the incidence of urinary tract infections in patients with heart failure: a pooled analysis of four trials including 26,838 patients
50. Effects of canagliflozin on cardiovascular death and hospitalisation for heart failure by eGFR: integrated analyses of the CANVAS Program and CREDENCE
51. Cardiovascular Outcomes of SGLT2 Inhibitors Across Sex or Race in Patients with/out Diabetes and Heart Failure
52. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
53. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis
54. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials
55. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
56. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
57. The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis
58. Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis

59. Optimal Pharmacologic Treatment of Heart Failure with Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis
60. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure
61. SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency.
62. SGLT-2 INHIBITORS ARE EFFICACIOUS IN HIGH-RISK SUBGROUPS OF PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION
63. Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events
64. "Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure Patients With Mildly Reduced and Preserved Ejection Fraction"
65. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials
66. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?